Search
Close this search box.

A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera®) For Stage I – II Low Grade Follicular Lymphoma

For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be cured.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG (NHLLOW 5); Princess Margaret Hospital, Toronto

Final Accrual

150

Closing Date of Accrual

July 2012

Trial Chairperson

A/Prof Michael Mac Manus, Peter MacCallum Cancer Centre, VIC

Trial Contact

Bev.McClure@petermac.org

Clinical Trial Registration

Related Post

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof